L ow molecular weight heparins (LMWHs) have largely replaced unfractionated heparin (UFH) in many clinical settings as a result of their predictable pharmacokinetics, eliminating the need for routine laboratory monitoring, convenient subcutaneous administration and non-inferior efficacy compared to UFH. Fixed or weight-based dosing and widespread use of pre-filled syringes provide a safety advantage over UFH through a reduction in the likelihood of medication error. For many indications, therapeutic efficacy is achieved with LMWH at a lower bleeding risk compared to UFH. However, facility-wide utilization of LMWH for all prophylactic and therapeutic indications has been impeded by a perception that patients with renal insufficiency cannot receive LWMH due to a risk of bioaccumulation leading to bleeding. Given the prevalence of acute and chronic kidney disease, renal impairment is a real concern for practicing clinicians considering the use of LWMH. In many facilities, UFH remains the default option for anticoagulating patients with renal impairment, despite the complexity of its use and its known toxicity profile.
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Park and colleagues 1 provide us with useful information in considering more widespread use of LMWH. Their retrospective cohort study examines clinical outcomes in a large group of patients treated with either UFH or dalteparin at therapeutic doses. Their seminal finding-more than a 60 % risk reduction for major bleeding in dalteparin-treated patients-should reassure clinicians that the LMWH dalteparin can be used safely at therapeutic doses in patients with a creatinine clearance (CrCl), determined using the MDRD equation, of less than 60 mL/minute. Their findings are particularly reassuring in patients with a CrCL of 30 to 60 mL/minute. Although the numeric risk reduction for bleeding was preserved in patients with a CrCl of less than 30 mL/minute, the difference in bleeding rates was not statistically significant; this was likely influenced by case-selection favoring use of UFH in patients with worse renal function and/or a higher bleeding risk as evidenced by a higher proportion of such patients receiving UFH than in the CrCl 30 to 60 mL/minute cohort (77 % of patients with a GFR of less than 30 mL/min in were treated with UFH, compared with 51 % of patients with a GFR of 30 to 60 mL/min).
The results of this study should be regarded with caution; as noted by the authors, its limitations include the non-randomized design, varying indications and duration of therapy, and inability to obtain highly reliable and uniform outcome data. The principal impact of the lack of randomization is the potential for low risk patients to have been selected for dalteparin treatment, resulting in an apparent reduction in bleeding complication in these patients.
As pointed out by the authors, this study should not be interpreted to demonstrate a "class effect." It is likely that the risk of bioaccumulation of LMWH will vary between preparations, based on their chemical characteristics. Thus, in combination with existing clinical literature, there is now evidence to support at least short courses of therapeutic dose dalteparin for patients with impaired renal function at usual weight-based doses and without routine anti-Xa activity monitoring. The same cannot be said for enoxaparin, where either an empiric 50 % dose reduction (which has an unknown impact on efficacy) or anti-Xa activity monitoring should be undertaken to ensure that bioaccumulation with bleeding does not occur. 2 Given the limitations of this study, can therapeutic dose dalteparin be used safely in patients with impaired renal function? In previous work, we failed to find evidence of bioaccumulation in critically ill patients with renal dysfunction receiving prophylactic dose dalteparin as assessed with anti-Xa activity. 3 Subsequently, in a large randomized trial, we failed to find an increase in bleeding when prophylactic dose dalteparin was compared with UFH in critically ill patients (in a study enrolling patients with the full range of impaired renal function, including patients with end stage disease requiring hemodialysis). 4 In a recent re-analysis of data from the seminal CLOT study, there were similar rates of bleeding in patients treated with dalteparin followed by oral anticoagulation (OAC) with warfarin compared to those treated with long-term dalteparin in the setting of both impaired renal function and cancer associated venous thromboembolism (frequency of any hemorrhage over 6 months of follow-up with dalteparin transitioned to OAC 24.1 % vs. 20.1 % with long-term dalteparin alone, p=NS).
What should the practicing clinician take away from this paper? Despite its methodological limitations, this study adds to a body of evidence suggesting that selected LWMHs can be used safely in patients with impaired renal function. Specifically for the LMWH dalteparin, there is very good quality evidence that at prophylactic doses it can be used without reference to renal function, while at therapeutic doses this paper supports its use, particularly in patients with a CrCl between 30 and 60 mL/minute. Use of LMWH in such patients would simplify therapy when compared with UFH, may reduce bleeding complications, probably reduces costs (due to reduced need for testing and nursing interventions), will reduce the frequency of heparininduced thrombocytopenia, and may allow selected patients to be treated outside the hospital setting. Ideally, the results of this study should be confirmed in a large randomized trial. However, such a study is unlikely to occur and our practice decisions will need to be informed by observational studies, such as that by Park and colleagues published in this issue of the journal.
